Clinical Perspective and Translational Oncology of Liquid Biopsy

• Main Authors: Diego Fernández-Lázaro, Juan Luis García Hernández, Alberto Caballero García, Aurora Caballero del Castillo, María Villaverde Hueso, Juan Jesús Cruz-Hernández
• Format: Article
• Language: English
• Published: MDPI AG 2020-06-01
• Series: Diagnostics
• Subjects: liquid biopsy; cancer detection; clinical practice; molecular profile; minimal residual disease; response monitoring
• Online Access: https://www.mdpi.com/2075-4418/10/7/443

The term liquid biopsy (LB) refers to the study of circulating tumor cells, circulating tumors nucleic acids free of cells or contained in exosomes, and information about platelets associated with tumors. LB can be performed in different biofluids and allows the limitations of tissue biopsy to be overcome offering possibilities of tumor identification reflecting in real time tumor heterogeneity. In addition, LB allows screening and early detection of cancer, real-time monitoring of therapy, stratification and therapeutic intervention, a therapeutic target and resistance mechanism, and a risk of metastatic relapse. Currently, LB has been shown to be effective for its application in different types of tumors including lung, colorectal, prostate, melanoma, breast and pancreatic cancer, by the determination and identification of biomarkers that with a high probability have the potential to change the way in which medical oncology could predict the course of the disease. These biomarkers make it possible to capture the heterogeneity of the cancer, monitor its clonal evolution, indicate new treatments or retreatments and evaluate the responses to different evolutionary and/or therapeutic pressures in the cancer disease.